ZHIFEI-BIOL: CA111 injection has received approval for clinical trials
I'm PortAI, I can summarize articles.
ZHIFEI-BIOL's subsidiary, Chen'an Biotech, has received clinical trial approval from the National Medical Products Administration for its CA111 injection, allowing trials to be conducted in overweight or obese adult patients. CA111 is a dual agonist that targets GIP and GLP-1 receptors, aimed at improving blood glucose control and weight loss through a synergistic mechanism
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments